604-688-0221 ext: 524


Bacchus Barua

Associate Director, Health Policy Studies, Fraser Institute

Bacchus Barua is Associate Director of the Fraser Institute’s Centre for Health Policy Studies. He completed his BA (Honours) in Economics at the University of Delhi (Ramjas College) and received an MA in Economics from Simon Fraser University. Bacchus has conducted research on a range of key health care topics including hospital performance, access to new pharmaceuticals, the impact of aging on health care expenditures, and international comparisons of health care systems. He also designed the Provincial Healthcare Index (2013) and is the lead author of The Effect of Wait Times on Mortality in Canada, and Waiting Your Turn: Wait Times for Health Care in Canada (2010–2014).

Recent Research by Bacchus Barua

— Dec 4, 2018
Printer-friendly version
Waiting Your Turn: Wait Times for Health Care in Canada, 2018 Report

Waiting Your Turn: Wait Times for Health Care in Canada, 2018 finds that the median wait time for medically necessary treatment in Canada this year was 19.8 weeks. Among the provinces, Saskatchewan has the shortest median wait time this year at 15.4 weeks, and New Brunswick again recorded the longest wait time (45.1 weeks).

— Nov 8, 2018
Printer-friendly version

Comparing Performance of Universal Health Care Countries, 2018 finds that Canada spends more on health care than a majority of 28 comparable countries with universal coverage, but ranks near the bottom in terms of the number of physicians and hospital beds, and Canada suffers from the longest wait times.

— Oct 16, 2018
Printer-friendly version
Provincial Drug Coverage for Vulnerable Canadians

Provincial Drug Coverage for Vulnerable Canadians finds that every province already provides prescription drug coverage to help Canadians—particularly seniors and lower-income Canadians—pay for pharmaceuticals. Crucially, provinces are able to establish prescription drug plans to suit their particular priorities, population age, income levels and other factors, which differ from province to province. This customization would likely be lost or at least diluted if Canada adopts a national pharmacare program.